| Literature DB >> 36203054 |
Lige Leng1, Ziqi Yuan2, Ruiyuan Pan3, Xiao Su2, Han Wang2, Jin Xue2, Kai Zhuang2, Ju Gao4, Zhenlei Chen2, Hui Lin2, Wenting Xie2, Huifang Li2, Zhenyi Chen5, Keke Ren6, Xiao Zhang7, Wenting Wang6, Zi-Bing Jin7, Shengxi Wu6, Xinglong Wang4, Zengqiang Yuan3, Huaxi Xu2, Hei-Man Chow8, Jie Zhang9,10,11.
Abstract
Microglial cells consume adenosine triphosphate (ATP) during phagocytosis to clear neurotoxic β-amyloid in Alzheimer's disease (AD). However, the contribution of energy metabolism to microglial function in AD remains unclear. Here, we demonstrate that hexokinase 2 (HK2) is elevated in microglia from an AD mouse model (5xFAD) and AD patients. Genetic deletion or pharmacological inhibition of HK2 significantly promotes microglial phagocytosis, lowers the amyloid plaque burden and attenuates cognitive impairment in male AD mice. Notably, the ATP level is dramatically increased in HK2-deficient or inactive microglia, which can be attributed to a marked upregulation in lipoprotein lipase (LPL) expression and subsequent increase in lipid metabolism. We further show that two downstream metabolites of HK2, glucose-6-phosphate and fructose-6-phosphate, can reverse HK2-deficiency-induced upregulation of LPL, thus supporting ATP production and microglial phagocytosis. Our findings uncover a crucial role for HK2 in phagocytosis through regulation of microglial energy metabolism, suggesting a potential therapeutic strategy for AD by targeting HK2.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36203054 DOI: 10.1038/s42255-022-00643-4
Source DB: PubMed Journal: Nat Metab ISSN: 2522-5812